EX-99.9 10 sinovacexh99_9.txt SINOVAC BIOTECH 6K, PRESS RELEASE 07.22.04 EXHIBIT 99.9 ------------ SINOVAC BIOTECH LTD. -------------------- FILES DRUG REGISTRATION FOR INTERNATIONAL MARKETS FOR ITS --------------------------------------------------------- HEPATITIS A VACCINE ------------------- Beijing, China, 22 July, 2004 - Sinovac Biotech Ltd. ("Sinovac") ("the Company") (NASD OTC-BB: SNVBF) announces vaccine registration applications for its Hepatitis A vaccine have been submitted in nine countries: Brazil, Indonesia, Mexico, Malaysia, Pakistan, Philippines, Sri Lanka, Thailand, and Vietnam. Each country's application requirements vary, and the Company is waiting on formal responses from official health authorities in each of these countries. Sinovac is currently experiencing strong sales growth of its Hepatitis A vaccine, Healive. Management of Sinovac is currently projecting domestic Chinese sales of approximately US $10 million for the current year ending 31st December 2004 - an increase of more than three times 2003 sales. Management expects to receive final approval of its combined Hepatitis A&B vaccine by the Chinese FDA in August, and expects to commence sales of this product by October, 2004. Sinovac intends to replicate its dramatic Chinese sales growth of Healive in the international marketplace. The company is energetically pursing global market development opportunities and achieving initial marketing strategy goals. Sinovac is actively developing its international market and collaborating with professional and well-rounded companies in order to accelerate its international marketing strategy, while simultaneously taking its advantage of its state-of-the-art R&D capabilities. To date, Sinovac has selected two experienced marketing and sales companies to assist in marketing its products in international markets. Innopath International, a Korean company, has enormous international vaccine market experience and a well-organized worldwide sales network. Innopath's management team is assisting Sinovac in developing its international sales. This assistance includes marketing strategy development, registration in some of the targeted countries, and the establishment of distribution channels through Innopath's existing relationships with vaccine distributors in the international market. Another international sales agent for Sinovac is China National Medicine & Health Products Import/Export Corporation (abbreviated in China as MEHECO). It is one China's largest import/export and domestic trade enterprises in the field of medicines and healthcare products with US$6.3 billion in its import and export business for the past 18 years. MEHECO has a reputation for nurturing diverse relationships with customers from more than one hundred countries and regions in the world. "These nine countries represent Sinovac's first foreign applications for its affordable world-class vaccines. These vaccine registration applications represent our initial international markets as we make progress towards sales in 32 targeted countries." stated Sinovac's president, Dr. Wei Dong Yin. About Sinovac Biotech Ltd. -------------------------- Sinovac Biotech Ltd. specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as Hepatitis A and Hepatitis B, influenza and "SARS." Sinovac is one of the leading emerging biotechnology companies in China. Working closely with Chinese public health officials, Sinovac focuses on manufacturing and marketing human-use vaccines and related products, and currently markets its vaccine for Hepatitis A. Sinovac is the first and currently the only company in the world to have been granted permission to begin clinical trials for a vaccine to prevent SARS. For further information please refer to the Company's filings with the SEC on EDGAR or refer to Sinovac's website at www.sinovac.com. --------------- Contact: Investor Relations at (888) 888 8312 or (604) 684-5990 or info@sinovac.com. ---------------- THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC'S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE "SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.